Our group and others have demonstrated that overexpression of SET, a potent PP2A endogenous inhibitor, is a recurrent event that causes PP2A inactivation in hematological neoplasms [5–8]. The gene discussed is PTPA; the disease is hematopoietic and lymphoid system neoplasm.